Volume 2, Issue 1

Asthma January 2022: Current State of the Art

In this issue:

The management of patients with asthma has evolved significantly, particularly for people on either end (mild and severe) of the symptom scale. Although the most consulted guidelines (NAEPP/NHLBI and GINA) have recently been updated, therapeutic advances have outpaced the guidance, leaving clinicians with questions about two of their key patient populations. 

What are the best (most recommended) management strategies for mild asthma? Which patients with severe asthma should be considered candidates for a biologic therapy? What are the indications for each therapy? 

Those are some of the questions Dr. Ashraf Fawzy from Johns Hopkins addresses in this issue of ePulmonology Review.

Learning objectives:

  • Identify management strategies for mild asthma and differences between NHLBI and GINA guidelines.
  • Describe indications for biologic therapy in severe asthma and the rationale for prescribing specific biologic therapies.


Ashraf Fawzy, MD, MPH
Ashraf Fawzy, MD, MPH

Assistant Professor of Medicine
Division of Pulmonary and Critical Care
Johns Hopkins University
Baltimore, Maryland

Program Directors:

Gregory B. Diette, MD

Professor of Medicine, Epidemiology and Environmental Health Sciences
Johns Hopkins University School of Medicine
Baltimore, Maryland

Christine Smith, RN, MSN

Senior Clinic Nurse Coordinator
Johns Hopkins Medicine
Baltimore, Maryland

Length of activity:

1.0 hour Physicians
1.0 contact hour Nurses

Launch date: January 6, 2022
Expiration date: January 5, 2024